Bristol-Myers Squibb Completes Amira Acquisition

Bristol-Myers Squibb said Thursday that it has completed its acquisition of privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

The deal was originally announced on July 21, and has met all customary regulatory approval obligations. As a result of the acquisition, Amira has become a wholly-owned subsidiary of Bristol-Myers Squibb.

The acquisition of Amira Pharmaceuticals' fibrosis program, including the lead asset AM152, an orally available lysophosphatidic acid 1 receptor antagonist which has completed Phase I clinical studies and is now poised for Phase Iia proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis and systemic Sclerosis, or scleroderma, marks Bristol-Myers Squibb's entrance into fibrotic diseases. Bristol-Myers Squibb also has obtained Amira's preclinical autotaxin program, which may be useful in the treatment of neuropathic pain and cancer metastases.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
24.03.2025 • News

Coco Custo – Clean Clothes, Cleaner Ingredients, Clean Sea

The Indian, woman-led startup Coco Custo is pioneering more sustainable cleaning solutions with its biodegradable laundry detergent and other eco-friendly cleaning powders. Formulated primarily from plant-based ingredients and minerals, including organic oils and coconut, Coco Custo’s products are non-toxic, hypoallergenic, and free from harmful chemicals.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.